Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel therapeutics candidates and technology platforms, including a $255m series C round for the artificial intelligence-based drug discovery and development firm Insilico Medicine.
A frequent collaborator with big pharma partners, Insilico announced the super-sized venture capital round on 22 June and said the proceeds would fund continued development of its AI-powered capabilities and be used to advance internally developed preclinical and clinical drug candidates
VC Deals In Depth
For detailed coverage of recent venture capital deals in Scrip, also see:
Intellia, Cellex Team Up On New CAR-T Firm, Backed By $250m From Blackstone
Apollo’s Next Steps: Apply Learnings From Prior Hub-And-Spoke Entities With $145m In New Capital
Novel CAR-T Start-Up Mnemo Bags €75m ($90m) Series A Financing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
